TRINTELLIX Drug Patent Profile

Which patents cover Trintellix, and when can generic versions of Trintellix launch?

Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventeen patent family members in forty-two countries.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Trintellix

Trintellix was eligible for patent challenges on September 30, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 30, 2031. This may change due to patent challenges or generic licensing.

There have been twenty-six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are three tentative approvals for the generic drug (vortioxetine hydrobromide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for TRINTELLIX

International Patents:	217
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	11
Patent Applications:	197
Drug Prices:	Drug price information for TRINTELLIX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRINTELLIX
What excipients (inactive ingredients) are in TRINTELLIX?	TRINTELLIX excipients list
DailyMed Link:	TRINTELLIX at DailyMed

See drug prices for TRINTELLIX

See drug sales revenues for TRINTELLIX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRINTELLIX

Constraining patent/regulatory exclusivity:

8,722,684*PED

NDA:

204447

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRINTELLIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seasons Biotechnology (Taizhou) Co., Ltd.	Phase 1
H. Lundbeck A/S	Phase 3
Todd Doyle	Phase 4

See all TRINTELLIX clinical trials

Paragraph IV (Patent) Challenges for TRINTELLIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRINTELLIX	Tablets	vortioxetine hydrobromide	5 mg, 10 mg, 15 mg and 20 mg	204447	15	2017-10-02

US Patents and Regulatory Information for TRINTELLIX

TRINTELLIX is protected by ten US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,722,684.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes	9,125,908*PED				Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No	9,861,630*PED				Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes	9,278,096*PED				Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No	9,227,946*PED				Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No	9,278,096*PED				Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No	9,125,908*PED				Y

Expired US Patents for TRINTELLIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-001	Sep 30, 2013	8,476,279
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013	8,476,279
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013	8,476,279
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-002	Sep 30, 2013	8,476,279

International Patents for TRINTELLIX

When does loss-of-exclusivity occur for TRINTELLIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

Japan

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRINTELLIX around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	061481
Argentina	065797
Austria	E495745
Austria	E540941
Australia	2007260355
Australia	2008228638

Supplementary Protection Certificates for TRINTELLIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1436271	300652	Netherlands		PRODUCT NAME: VORTIOXETINE OF EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT ERVAN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218
1436271	C300652	Netherlands		PRODUCT NAME: VORTIOXETINE OF EEN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218
1436271	PA2014013	Lithuania		PRODUCT NAME: VORTIOXETINUM; REGISTRATION NO/DATE: EU/1/13/891 20131218
1436271	92397	Luxembourg		PRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE
1436271	CR 2014 00030	Denmark		PRODUCT NAME: VORTIOXETIN ELLER FARMACEUTISK ACCEPTABLE SYREADDITIONSSALTE DERAF, HERUNDER VORTIOXETINHYDROBROMID; REG. NO/DATE: EU/1/13/891 20131218
1436271	14C0033	France		PRODUCT NAME: VORTIOXETINE OU L'UN DE SES SELS D'ADDITION D'ACIDE PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/891 20131218

Trintellix (vortioxetine) market dynamics and financial trajectory (2024–2029): exclusivity, competitive pressures, and revenue exposure

Last updated: July 29, 2026

Trintellix (vortioxetine) revenue has been pressured by generic and branded-competition dynamics since the loss of branded exclusivity in the US and by persistent payer steering toward lower-cost alternatives. The near-term revenue outlook is driven by (1) remaining line-of-therapy demand, (2) formulary position and prior authorization patterns, (3) price erosion versus generics, and (4) geography-specific patent and exclusivity tail.

---

How much revenue does Trintellix generate and what is its current growth trajectory?

Featured snippet answer: Trintellix has shifted from a branded growth profile to a late-stage revenue profile driven mainly by formularies that still carry vortioxetine (brand or authorized generic), with top-line growth limited by generic price compression and substitution.

US revenue trajectory: branded vs. vortioxetine generics

Key market dynamic is substitution after generic entry, which compresses net price and reduces incremental sales growth even when total treated populations remain stable. In practical terms:

• Once FDA approval of ANDAs occurs for vortioxetine, retail and PBM reimbursement tends to shift patients to the lowest-cost covered product.
• Brand-to-generic switching is reinforced by coverage tiers and step therapy when payers set “preferred SSRI/SNRI” or “preferred antidepressant” policies.

EU/UK trajectory: slower brand erosion, but class-level competition persists

Outside the US, net price erosion typically lags generic penetration due to:

• country-by-country generic timing
• reimbursement and reference-pricing rules
• local marketing and contracting structures
• jurisdiction-specific patent and supplementary protection certificate (SPC) tail for specific product/indication protection

What matters for financial modeling

For a drug like vortioxetine, the financial trajectory is usually best modeled using:

• net sales = (TRx volume) × (net price per TRx)
• TRx volume = (eligible patient pool) × (share of prescriptions among antidepressants) × (persistence/med continuation)
• net price = brand net price ÷ branded displacement plus generic mix effect

---

What patents and exclusivity still matter for Trintellix, and when does exclusivity lose?

Featured snippet answer: Trintellix’s market exclusivity in the US is not the key driver of ongoing revenue because generic entry has already occurred; the remaining value is tied to geography-specific patent estates, indication-specific protection, and formulation or method-of-use coverage (where still active).

Patent landscape impact on commercial duration

Trintellix revenue endurance depends on whether active patent coverage:

• blocks generic manufacturing at launch for additional dosage forms or presentations
• protects specific clinical uses (method-of-use)
• extends brand viability via controlled-switching or authorized-generic strategy

Timing question: when does Trintellix face new generic entry risk?

For most investors, “new risk” is less about the first generic launch and more about:

• additional ANDA filings for alternate dosage forms
• “design-around” challenges for new polymorphs, crystallization processes, or controlled-release variants
• indication-specific protection that can delay substitution in defined label-driven segments

---

What is the Orange Book status of Trintellix (vortioxetine), and how does it drive generic entry risk?

Featured snippet answer: The Orange Book is the practical control panel for generic substitution risk because it lists patents that can trigger Paragraph IV litigation and potentially delay FDA approval.

How Orange Book listings translate into market outcomes

Orange Book-listed patents influence Trintellix market dynamics via:

• Paragraph IV incentives for generic filers
• settlement leverage that can shift “launch” dates (skinny label vs full label)
• channel substitution timing (pharmacy substitution rules follow FDA approval dates, not marketing plans)

Practical “Orange Book to revenue” link

Even when primary composition-of-matter protection is expired, Orange Book listings can:

• preserve a protected label for certain indications or patient cohorts
• sustain PBM preference for brand longer than generic market entry alone would imply

---

How many patents cover Trintellix formulations, methods of use, and manufacturing, and which are most commercially important?

Featured snippet answer: The commercially important patent subset is typically narrower than the total estate. For revenue, the high-impact patents are those that block FDA approval for a directly substitutable product and label.

Patent estate categories that matter

• Composition and crystal form
• Process/manufacturing methods
• Formulation and dosage presentation (including film coating or solvate/polymorph-related manufacturing controls)
• Method-of-use patents (indication-specific label claims)
• Use in combination regimens (less common in antidepressant dynamics, but can exist)

Where investors should focus in the Trintellix estate

• Patents still listed on the Orange Book at the time of generic ANDA consideration
• Patents that map to the narrowest label that drives prescribing (eg, major depressive disorder)

---

What generic or biosimilar competition exists for Trintellix (vortioxetine), and how does it compare with other antidepressants?

Featured snippet answer: Trintellix competes primarily with generics of vortioxetine and with branded and generic SSRI/SNRI alternatives, not with biosimilars (vortioxetine is a small molecule).

Competitive set: antidepressant class dynamics

Payers segment antidepressant choice using:

• efficacy for specific endpoints (response/remission in major depressive disorder)
• tolerability profile (GI effects, sexual dysfunction, discontinuation symptoms)
• safety and monitoring requirements
• formulary placement strategy

How Trintellix compares commercially

Trintellix’s share dynamics tend to be shaped by:

• branded “differentiation” in early launch years
• later displacement when net prices for vortioxetine generics converge with SSRIs/SNRIs
• shifting physician preference due to non-brand evidence such as comparative effectiveness and local experience

---

Which companies are challenging Trintellix with ANDAs or Paragraph IV filings?

Featured snippet answer: The Paragraph IV landscape is directly relevant to short-run price and launch timing, but the commercial direction after generic entry is dominated by formulary placement and net price erosion.

How Paragraph IV outcomes influence market pricing

For small molecules like vortioxetine, the settlement structure and court outcomes affect:

• which generic filers launch first
• whether a “limited launch” occurs (eg, skinny label or partial coverage)
• time-to-file for additional ANDAs, which accelerates competition and compresses net price

---

What Trintellix patent litigation and settlements affected generic launch timing?

Featured snippet answer: Patent litigation is the gating function for the first generics and for any delay in market entry. After the first waves of generic entry, revenue is increasingly determined by PBM formulary positioning and ongoing generic mix.

What to track for litigation-driven revenue changes

• first approval date of each ANDA
• court-triggered or settlement-triggered delay end dates
• any changes in label scope tied to settlement “carve-outs”

---

What is the FDA regulatory status of Trintellix, including approvals, labeling, and switching dynamics?

Featured snippet answer: The clinical status of vortioxetine remains anchored in major depressive disorder labeling, while competitive dynamics depend on payer policy and substitution rules once generics are available.

FDA pathway relevance to market access

• Brand access vs generic substitution follows FDA approval and PBM contracting cycles.
• Any formulation changes that add dosage strengths or presentations can create temporary non-substitutability if generics are not immediately available for the specific NDC.

---

How do dosing, formulation, and line-of-therapy patterns influence Trintellix financial performance?

Featured snippet answer: Sustained TRx volume is driven by dosing persistence and tolerability-driven continuation, while financial performance depends on the net price mix between brand, authorized generic, and full generic.

Dosing and switching sensitivity

Antidepressant switching is sensitive to:

• adverse event profile and discontinuation symptoms
• patient history with SSRIs and SNRIs
• prescriber habits after initial stabilization

Real-world persistence effects

If real-world persistence is high, TRx volume declines more slowly after generic penetration. If switching is common due to tolerability, volume erodes faster and net sales fall faster once brand is displaced.

---

What revenue risks exist for Trintellix from new generic entry, authorized generics, or formulation workarounds?

Featured snippet answer: The main incremental revenue risks are accelerated price compression from additional ANDA entrants, authorized generic availability, and substitution of specific NDCs that are currently less contested.

Generic launch scenarios that shift revenue quickly

• First-to-market generic gets a pricing floor advantage
• Subsequent entrants expand discounting and increase PBM leverage
• Authorized generic reduces brand’s “net price tail” by offering wholesalers and PBMs a low-cost alternative even when brand remains contracted

---

How does Trintellix’s patent and commercial profile compare with competing antidepressants like Brintellix (same class/ingredient family) and key SSRI/SNRI peers?

Featured snippet answer: Trintellix competes in a crowded antidepressant market where patent-driven branded duration matters mainly early; once generics enter, performance hinges on residual differentiation, payer placement, and patient-level tolerability outcomes.

Comparative commercial dimensions

• Patent duration: impacts early branded revenue ceiling
• Net price: determines ability to maintain formulary preference
• Safety/tolerability: influences switching rates across antidepressant classes
• PBM contracting: determines how quickly branded share collapses after generic entry

---

Geographic market exposure: which regions drive remaining Trintellix value and where is erosion fastest?

Featured snippet answer: Regions where generic penetration occurred later or where reimbursement remains more favorable to vortioxetine preserve longer brand-like economics. Faster erosion correlates with earlier generic approvals and tighter reference pricing.

What to watch by region

• US: fastest price compression after generic waves
• EU large markets: slower dislocation due to country-specific entry timing and tender practices
• Emerging markets: access and pricing depend on local manufacturing and reimbursement maturity

---

Key takeaways for investors and brand owners

• Trintellix’s revenue trajectory is primarily a post-generic displacement story rather than a protected-exclusivity story.
• The highest leverage variables are PBM formulary position, net price mix (brand vs authorized generic vs full generic), and patient persistence.
• Litigation and Orange Book status still matter, but largely for launch timing of additional dosage forms and new entrant waves, which then accelerate net price compression.
• In antidepressants, total treated population growth is rarely enough to offset displacement; valuation models must focus on net price and share, not just market size.

---

FAQs

1) What drives Trintellix prescription volume after generic entry?
Patient persistence, tolerability, and prescriber familiarity determine whether TRx volume holds up despite net price erosion.

2) Does Trintellix face biosimilar competition?
No. Vortioxetine is a small-molecule drug, so the competitive threat is generic small-molecule substitution and class-level antidepressant competition.

3) How do payer restrictions like prior authorization affect Trintellix revenue?
They can slow brand displacement and maintain a premium net price in pockets where coverage requires specific prior trial history.

4) What factors influence which generic NDCs gain the fastest share?
Wholesaler distribution, rebate/discount contracting, and PBM tiering decide whether the first entrants capture most prescriptions.

5) What is the most common commercialization risk after a generic launch?
Rapid net price compression as additional generic entrants expand discounting and reduce the brand’s ability to sustain formulary preference.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. FDA prescribing information for Trintellix (vortioxetine). (Accessed 2026).
3. FDA Drug Approval Reports for vortioxetine (Trintellix). (Accessed 2026).

DrugChatter Q&A for TRINTELLIX

Does trintellix cause anxiety?
Trintellix patent extention?
When generic trintellix in canada?
Patent expire trintellix brintellix vortioxetin generica germany reddit?
When is trintellix loosing the patent?